Topics

Companies Related to "Environmental Factors Associated with Inflammatory Bowel Disease" [Most Relevant Company Matches] RSS

10:48 EDT 17th September 2019 | BioPortfolio

Here are the most relevant search results for "Environmental Factors Associated with Inflammatory Bowel Disease" found in our extensive corporate database of over 50,000 company records.

Showing "Environmental Factors Associated with Inflammatory Bowel Disease" Companies 1–25 of 3,800+

Extremely Relevant

Aerpio Therapeutics

Aerpio Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease. Aerpio is a leader in the development of small molecule drugs based on Tie-2 activation and the stabilization of Hypoxia-inducible Factor 1α (HIF-1α). The company’s ...


Aerpio Therapeutics, Inc.

Aerpio Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease. Aerpio is a leader in the development of small molecule drugs based on Tie2 activation and the stabilization of Hypoxia-inducible Factor 1α (HIF‐1α). The Company...

SFA Therapeutics

SFA Therapeutics is a bio-pharmaceutical company focused on new advancements in the treatment of inflammatory diseases, targeting NF-κB. Chronic inflammation has been implicated in a wide range of diseases, including rheumatoid arthritis, psoriatic arthritis, lupus (SLE), inflammatory bowel disease (IBD), Crohn's Disease, psoriasis, liver disease a...


Relevant

SFA Therapeutics, Inc.

SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-KB mediated pathways. Chronic inflammation has been implicated in a wide range of diseases, including Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease ...

The Pediatric Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center

Proteostasis Therapeutics and Elan Corporation

Proteostasis Therapeutics is developing “Proteostasis Regulators” (PRs), small molecule drugs that restore proper protein function or remove misfolded and aggregated proteins to treat neurodegenerative, metabolic, genetic and inflammatory disorders. The Proteostasis Network is the cellular machinery responsible for protein folding, trafficking and ...

AM‐Pharma B.V.

AM‐Pharma is a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase as protective treatment of acute kidney injury and inflammatory bowel diseases. AM‐Pharma is based in Bunnik, The Netherlands. Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in Acute Kidney Injury and ...

AM-Pharma B.V.

AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase as protective treatment of acute kidney injury and inflammatory bowel diseases. AM-Pharma is based in Bunnik, The Netherlands. Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in Acute Kidney Injury and a P...

4SC AG

4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in a Phase IIb study in rheumatoid arthritis and a Phase IIa exploratory study in inflammatory bowel disease. The company's lead oncology compound, resminostat (4SC-201), a pan histone d...

Atlantic Healthcare plc

Atlantic Healthcare is an international specialty pharmaceutical company focussed on diseases of the gastrointestinal tract and Inflammatory Bowel Disease (IBD). The Company's lead product is alicaforsen enema, in Phase 3 development for pouchitis, and in preparation for Phase 3 clinical development for Ulcerative Colitis. Alicaforsen is also generating ea...

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in...

OxyPharma AB

OxyPharma's lead compound B-220 has its origin in anti-viral research conducted by Professor Jan Bergman between 1971 and 1975. In the following years and financed by Kabi – a Swedish pharmaceutical company Professor Bergman synthesized the substance. Its anti-viral properties were confirmed in collaboration with the Bacteriological Laboratory of Sweden (SBL). Professor Bergman continued his res...

Alivio Therapeutics

Alivio Therapeutics, an affiliate of PureTech Health (PRTC.L), is pioneering targeted disease immunomodulation to treat a range of chronic and acute inflammatory disorders. Targeted disease immunomodulation involves acting exclusively at the site of inflammation rather than systemically, to minimize impacts on the wider immune system and healthy tissue. To...

Novogen

Novogen's business is in the most pressing area facing medicine in the modern era - that of degenerative diseases and disorders. Cancer Heart disease (stroke, hypertension, coronary artery disease) Osteoporosis Rheumatoid arthritis Inflammatory Bowel Disease (ulcerative colitis, Crohn's Disease) Neurological diseases (Parkinson's Disease, motor neurone disease) Autoimmune diseases (m...

Amakem

Amakem NV is a biopharmaceutical company developing safe and effective kinase inhibitors using its "Localized Drug Action" platform for the treatment of diseases, such as COPD, glaucoma and inflammatory bowel disease. The company focuses on the development of promising and innovative near clinical or clinical small molecule drugs.

Incara Pharmaceuticals Corporation

Incara Pharmaceuticals Corporation conducts discovery and development programs in three areas: (1) inflammatory bowel disease, using an ultra-low molecular weight heparin; (2) liver disorders, using a novel form of hepatic progenitor cell therapy; and (3) novel small molecule antioxidants for disorders such as stroke, asthma and reperfusion injury.

Cequent Pharmaceuticals, Inc.

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders -- from inflammatory disease to cancer -- based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi(TM)). Cequent's first products, now entering clinical development, are orally administered drug candidates targeting c...

Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics (PTI) is developing novel disease-modifying therapeutics that target the cellular pathways regulating protein folding, trafficking, and clearance. The Proteostasis Network (PN) is comprised of these interconnected cellular pathways and can become imbalanced by the cumulative effects of aging, disease, genetics and environmental fa...

GT Biologics

GT Biologics is focused on the research and development of Live Biotherapeutics (LBPs) for the treatment of autoimmune diseases. GT Biologics aim to deliver a new class of medicine based on the potent immune-regulating properties of novel bacterial isolates derived from the healthy human gut. We have completed a research-intensive innovative programme spanning several years investigating the i...

Microbiotica

Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute. The Company was founded by Dr Mike Romanos, Dr Trevor Lawley and Profess...

Landos Biopharma, Inc.

Landos Biopharma, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, locally-acting small molecule targeting inflammatory bowel disease (IBD) that is expected to enter clinical testing for Crohn’s...

Epistem Ltd

Epistem are epithelial tissue and adult stem cell experts, delivering innovative preclinical contract research services in the areas of oncology, mucositis, biomarker identification, inflammatory bowel disease, wound healing and skincare. Working with over 90 pharmaceutical, biotechnology, and personal care companies worldwide, we offer proprietary assays for target validation, in vitro screening...

Avexxin

Avexxin is a pharmaceutical company focused on developing and commercializing novel small molecule therapeutics for patients with chronic inflammatory conditions. Avexxin's advanced understanding of the biology of the inflammatory process has resulted in a novel therapeutic approach for the treatment of psoriasis and other inflammatory disorders. Our discovery and clinical development expertise is...

Shield Therapeutics

Shield, founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield is currently preparing to undertake a global pivotal Phase III study of its lead asset, ST10-021, for the treatment of iron deficiency anaemia associated with i...

Progenity Inc.

Progenity is a biotechnology company with a market-leading presence in Women’s Health molecular testing and a pipeline of proprietary tests and therapeutic applications under development. Progenity has a portfolio of innovative technologies and tests for pre-eclampsia, genetic carrier testing, inheritable cancer genetics, liquid biopsy and noninvasive ...


More From BioPortfolio on "Environmental Factors Associated with Inflammatory Bowel Disease"

Quick Search

Corporate Database Quicklinks